DDInter806 DDInter1657
An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.[L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant. Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2 lines of systemic therapy. The FDA approved Selinexor in June 2019. The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Ganciclovir {u} (Compound) resembles {v} (Compound) Penciclovir
Ganciclovir {u} (Compound) resembles {v} (Compound) Valaciclovir
Ganciclovir {u} (Compound) binds {v} (Gene) SLC22A8
Ganciclovir {u} (Compound) upregulates {v} (Gene) PAK1
Ganciclovir {u} (Compound) is included by {v} (Pharmacologic Class) DNA Polymerase Inhibitors
Ganciclovir {u} (Compound) downregulates {v} (Gene) CANT1
Ganciclovir {u} (Compound) causes {v} (Side Effect) Creatinine increased
Ganciclovir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eribulin
Ganciclovir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Irinotecan
Ganciclovir {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Ganciclovir (Compound) resembles Penciclovir (Compound)
Ganciclovir (Compound) resembles Valaciclovir (Compound)
Ganciclovir (Compound) binds SLC22A8 (Gene)
Ganciclovir (Compound) upregulates PAK1 (Gene)
Ganciclovir (Compound) is included by DNA Polymerase Inhibitors (Pharmacologic Class)
Ganciclovir (Compound) downregulates CANT1 (Gene)
Ganciclovir (Compound) causes Creatinine increased (Side Effect)
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan
Ganciclovir may lead to a major life threatening interaction when taken with Certolizumab pegol